Stock listing
NASDAQ:IPSC Century Therapeutics, Inc. Stock
Home listing (NASDAQ) of Century Therapeutics, Inc.
Follow Century Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:IPSC
$1.17 USD -0.21 (-15.6%)
Close on Nov 20, 2026
- Day range
- $1.16 – $1.32 USDNov 20, 2026
- Volume
- 916,108 sharesNov 20, 2026
- Market cap
- $211.6M USDAt the close on Nov 20, 2026 · price × 181.6M shares outstanding
- 52-week range
- $0.464 – $3.04 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.21M USDMedian day 608,755 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:IPSC · Home | $1.165 USD | -0.215 (-15.6%) | 916,108 | $1.32 | $1.32 | $1.16 | $1.38 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IPSC · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.165 | -0.215 | -15.6% | $1.32 | $1.32 | $1.16 | 916,108 | |
| $1.38 | +0.01 | +0.7% | $1.36 | $1.46 | $1.32 | 1,142,209 | |
| $1.37 | -0.27 | -16.5% | $1.64 | $1.64 | $1.35 | 695,954 | |
| $1.64 | -0.01 | -0.6% | $1.65 | $1.705 | $1.57 | 909,925 | |
| $1.65 | +0.02 | +1.2% | $1.62 | $1.68 | $1.565 | 373,172 | |
| $1.63 | -0.11 | -6.3% | $1.75 | $1.75 | $1.60 | 608,755 | |
| $1.74 | +0.06 | +3.6% | $1.735 | $1.75 | $1.64 | 327,716 | |
| $1.68 | -0.13 | -7.2% | $1.78 | $1.85 | $1.63 | 720,025 | |
| $1.81 | +0.13 | +7.7% | $1.71 | $1.90 | $1.64 | 1,460,093 | |
| $1.68 | +0.17 | +11.3% | $1.52 | $1.73 | $1.48 | 1,896,472 | |
| $1.51 | -0.16 | -9.6% | $1.66 | $1.685 | $1.50 | 561,307 | |
| $1.67 | +0.15 | +9.9% | $1.58 | $1.77 | $1.52 | 749,287 | |
| $1.52 | +0.04 | +2.7% | $1.49 | $1.67 | $1.43 | 773,524 | |
| $1.48 | +0.01 | +0.7% | $1.49 | $1.535 | $1.46 | 1,128,455 | |
| $1.47 | +0.01 | +0.7% | $1.46 | $1.495 | $1.37 | 951,059 | |
| $1.46 | -0.04 | -2.7% | $1.53 | $1.55 | $1.415 | 1,445,878 | |
| $1.50 | +0.05 | +3.4% | $1.44 | $1.505 | $1.43 | 839,754 | |
| $1.45 | +0.03 | +2.1% | $1.40 | $1.48 | $1.38 | 771,261 | |
| $1.42 | -0.04 | -2.7% | $1.43 | $1.45 | $1.39 | 493,653 | |
| $1.46 | -0.12 | -7.6% | $1.55 | $1.57 | $1.44 | 892,067 | |
| $1.58 | -0.03 | -1.9% | $1.61 | $1.75 | $1.565 | 1,766,209 | |
| $1.61 | -0.03 | -1.8% | $1.65 | $1.67 | $1.525 | 1,678,418 | |
| $1.64 | +0.17 | +11.6% | $1.49 | $1.745 | $1.40 | 1,402,635 | |
| $1.47 | +0.10 | +7.3% | $1.38 | $1.505 | $1.32 | 586,235 | |
| $1.37 | -0.13 | -8.7% | $1.50 | $1.55 | $1.37 | 722,500 | |
| $1.50 | +0.12 | +8.7% | $1.38 | $1.52 | $1.36 | 927,200 | |
| $1.38 | 0.00 | 0.0% | $1.36 | $1.44 | $1.31 | 1,271,300 | |
| $1.38 | -0.06 | -4.2% | $1.44 | $1.44 | $1.35 | 544,200 | |
| $1.44 | -0.03 | -2.0% | $1.47 | $1.51 | $1.44 | 390,900 | |
| $1.47 | +0.01 | +0.7% | $1.46 | $1.55 | $1.42 | 816,800 | |
| $1.46 | +0.18 | +14.1% | $1.26 | $1.46 | $1.219 | 1,521,000 | |
| $1.28 | -0.04 | -3.0% | $1.29 | $1.32 | $1.27 | 697,200 | |
| $1.32 | -0.16 | -10.8% | $1.48 | $1.50 | $1.29 | 2,714,200 | |
| $1.48 | -0.05 | -3.3% | $1.58 | $1.59 | $1.455 | 771,300 | |
| $1.53 | -0.08 | -5.0% | $1.64 | $1.67 | $1.465 | 803,000 | |
| $1.61 | -0.10 | -5.8% | $1.65 | $1.695 | $1.595 | 619,400 | |
| $1.71 | +0.06 | +3.6% | $1.67 | $1.72 | $1.66 | 623,700 | |
| $1.65 | -0.02 | -1.2% | $1.66 | $1.67 | $1.63 | 353,500 | |
| $1.67 | 0.00 | 0.0% | $1.66 | $1.715 | $1.62 | 409,000 | |
| $1.67 | -0.02 | -1.2% | $1.70 | $1.78 | $1.63 | 457,000 | |
| $1.69 | -0.07 | -4.0% | $1.77 | $1.77 | $1.68 | 545,200 | |
| $1.76 | -0.13 | -6.9% | $1.89 | $1.938 | $1.76 | 508,100 | |
| $1.89 | +0.04 | +2.2% | $1.88 | $1.94 | $1.85 | 414,100 | |
| $1.85 | -0.01 | -0.5% | $1.87 | $1.905 | $1.829 | 421,000 | |
| $1.86 | -0.02 | -1.1% | $1.88 | $1.88 | $1.815 | 1,369,400 | |
| $1.88 | +0.02 | +1.1% | $1.89 | $1.94 | $1.83 | 430,200 | |
| $1.86 | -0.12 | -6.1% | $2.00 | $2.06 | $1.86 | 839,400 | |
| $1.98 | -0.02 | -1.0% | $2.00 | $2.00 | $1.93 | 359,600 | |
| $2.00 | +0.06 | +3.1% | $1.96 | $2.02 | $1.89 | 507,600 | |
| $1.94 | 0.00 | 0.0% | $1.98 | $2.00 | $1.89 | 465,700 | |
| $1.94 | -0.09 | -4.4% | $2.03 | $2.03 | $1.91 | 510,000 | |
| $2.03 | -0.04 | -1.9% | $2.07 | $2.10 | $2.03 | 293,100 | |
| $2.07 | -0.04 | -1.9% | $2.10 | $2.13 | $2.03 | 228,100 | |
| $2.11 | +0.02 | +1.0% | $2.06 | $2.15 | $2.06 | 300,000 | |
| $2.09 | -0.02 | -0.9% | $2.13 | $2.13 | $2.05 | 349,600 | |
| $2.11 | +0.08 | +3.9% | $2.03 | $2.135 | $2.03 | 465,800 | |
| $2.03 | -0.02 | -1.0% | $2.00 | $2.04 | $1.98 | 320,500 | |
| $2.05 | +0.025 | +1.2% | $2.00 | $2.06 | $1.97 | 373,900 | |
| $2.025 | -0.205 | -9.2% | $2.23 | $2.25 | $1.99 | 629,300 | |
| $2.23 | +0.09 | +4.2% | $2.15 | $2.25 | $2.15 | 525,700 | |
| $2.14 | -0.03 | -1.4% | $2.17 | $2.17 | $2.10 | 313,500 | |
| $2.17 | +0.05 | +2.4% | $2.13 | $2.205 | $2.12 | 542,815 | |
| $2.12 | +0.05 | +2.4% | $2.08 | $2.145 | $2.03 | 360,771 | |
| $2.07 | +0.05 | +2.5% | $2.05 | $2.085 | $2.02 | 330,600 | |
| $2.02 | -0.09 | -4.3% | $2.07 | $2.09 | $2.019 | 314,100 |
- Ticker
- NASDAQ:IPSC
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Century Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Latest deck · Oct 2, 2026
Technical Presentation (October 2026)
Technical · 19 slides
Latest news
Century Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Nov 12, 2026
Closed $1.63 (-6.3%) on Nov 12, 2026
Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London
Oct 14, 2026
Closed $1.38 (0.0%) on Oct 14, 2026
Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
Oct 2, 2026
Closed $1.53 (-5.0%) on Oct 2, 2026
Century Therapeutics Appoints Joseph Truitt to Board of Directors
Sep 9, 2026
Closed $1.94 (-4.4%) on Sep 10, 2026
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Aug 12, 2026
Closed $1.96 (-4.9%) on Aug 12, 2026
IHI Power Services Corp. Rebrands as Kyuden Energy Partners Following Acquisition by Japan's Kyuden Group
Jul 23, 2026
Closed $2.17 (+0.9%) on Jul 23, 2026
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
Jul 9, 2026
Closed $2.31 (-4.9%) on Jul 9, 2026
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
Jun 8, 2026
Closed $2.12 (-0.5%) on Jun 8, 2026
Century Therapeutics Reports First Quarter Financial Results and Business Updates
May 13, 2026
Closed $2.28 (-0.4%) on May 13, 2026
Century Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 94 in all · newest Nov 12, 2026 · oldest 2021
- Decks
- 35 decks · latest Oct 2, 2026
Where Century Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:IPSC · Home listing · This page | NASDAQ | United States | USD |
| BOATS:IPSC | BOATS | United States | USD |
Valuation
Price/book 1.0× against a median of 1.8×: 2nd lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $131.9M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.0×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.2×
- Beta vs S&P 500
- 2.35
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Century Therapeutics, Inc. · NASDAQ:IPSC | US$211.6M | US$131.9M | n/a | n/a | n/a | 1.0× | n/a | 0.2× | 2.35 |
| ProKidney Corp. · NASDAQ:PROK | US$217.3M | US$77.56M | n/a | 100× | n/a | n/a | n/a | n/a | 1.61 |
| Pyxis Oncology, Inc. · NASDAQ:PYXS | US$216.5M | US$160.9M | n/a | n/a | n/a | 5.2× | n/a | 0.0× | 0.89 |
| Oryzon Genomics SA · BME:ORY | US$216.4M | US$206.7M | n/a | n/a | n/a | 1.6× | n/a | 0.1× | n/a |
| Rocket Pharmaceuticals, Inc. · NASDAQ:RCKT | US$214.1M | −US$25.02M | n/a | n/a | n/a | 0.7× | n/a | 0.1× | 1.72 |
| Orum Therapeutics, Inc. · KRX:475830 | US$212.5M | US$24.22M | 15.4× | n/a | n/a | 1.5× | n/a | 0.0× | n/a |
| GemVax & KAEL Co Ltd · KRX:082270 | US$212.3M | US$207.4M | n/a | 3.3× | 21.2× | 3.8× | −14.4% | 0.4× | n/a |
| Transgene SA · EURONEXT:TNG | US$212.2M | US$112.7M | n/a | 750× | n/a | 1.8× | n/a | 0.0× | n/a |
| Arcturus Therapeutics Holdings Inc. · NASDAQ:ARCT | US$211.8M | US$45.18M | n/a | 1.5× | n/a | 1.3× | −285.9% | 0.1× | 2.01 |
| AnnJi Pharmaceutical Co., Ltd. · TPEX:7754 | US$209.9M | US$196.0M | n/a | 855× | n/a | 16.5× | n/a | 0.0× | n/a |
| Racura Oncology Ltd · ASX:RAC | US$207.6M | US$184.9M | n/a | n/a | n/a | 8.6× | n/a | 0.0× | n/a |
| Median of the others | US$212.4M | US$136.8M | 15.4× | 100× | 21.2× | 1.8× | −150.1% | 0.0× | 1.67 |
Forecasts
3 strong buy · 1 buy · 1 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.75 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.52 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Brent Pfeiffenberger | President and Chief Executive Officer |
| Krista Kauppinen | VP, General Counsel & Head of Intellectual Property |
| Century Therapeutics Douglas Carr Senior | Vice President |
| Elizabeth Devlin | VP, Head of Development |
| Chad Cowan | Chief Scientific Officer |
| Douglas Carr | Principal Financial Officer |
| Greg Russotti | Chief Technology and Manufacturing Officer |
| Megan Bilson | Chief People Officer |
Board
| Director | Role |
|---|---|
| Joseph Truitt | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | −6.3% |
| Q2 2026 | Aug 12, 2026 · Before open | −4.8% |
| Q1 2026 | May 13, 2026 · Before open | −0.4% |
| Q4 2025 | Mar 12, 2026 | −14.3% |
| Q3 2025 | Nov 13, 2025 · Before open | −17.5% |
| Q2 2025 | Aug 14, 2025 · After close | +2.1% |
| Q1 2025 | May 15, 2025 · After close | +8.2% |
| Q4 2024 | Mar 19, 2025 | −6.5% |
| Q3 2024 | Nov 5, 2024 · Before open | +5.6% |
| Q2 2024 | Aug 8, 2024 · Before open | +4.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · Before open | −1.0% |
| Q4 2023 | Mar 14, 2024 · Before open | −7.2% |
| Q3 2023 | Nov 9, 2023 · Before open | −13.1% |
| Q2 2023 | Aug 9, 2023 · Before open | −1.7% |
| Q1 2023 | May 11, 2023 · Before open | −1.8% |
| Q4 2022 | Mar 16, 2023 · Before open | −1.2% |
| Q3 2022 | Nov 10, 2022 · Before open | +15.1% |
| Q2 2022 | Aug 11, 2022 · Before open | −3.7% |
| Q1 2022 | May 16, 2022 · Before open | +9.8% |
| Q4 2021 | Mar 17, 2022 · Before open | −1.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (October 2026) | Technical | 19 slides | Oct 2, 2026 |
| Investor Presentation (August 2026) | Investor deck | 31 slides | August 2026 |
| Technical Presentation (June 2026) | Technical | 17 slides | Jun 8, 2026 |
| Corporate Update (March 2026) | Corporate update | 38 slides | Mar 12, 2026 |
| Investor Presentation (January 2026) | Investor deck | 38 slides | Jan 12, 2026 |
| Investor Presentation (January 2026) | Investor deck | 36 slides | Jan 8, 2026 |
| Technical Presentation (2026) | Technical | 19 slides | 2026 |
| Investor Presentation (December 2025) | Investor deck | 35 slides | Dec 12, 2025 |
| Investor Presentation (November 2025) | Investor deck | 34 slides | Nov 13, 2025 |
| Investor Presentation (August 2025) | Investor deck | 36 slides | Aug 14, 2025 |
All 35 decks
Financings
| Raise | Date |
|---|---|
| Private placement of shares of common stock (or pre-funded warrants) and accompanying warrants Announced: about US$135M · US$1.15 a share · Warrants at US$2.6 · Leerink Partners +2 Dealers: Leerink Partners, TD Cowen, Mizuho Buyers: TCGX; RA Capital Management; Commodore Capital; Deep Track Capital; RTW Investments; Venrock Healthcare Capital Partners; T1D Fund Use of proceeds: Fund development of lead product candidate CNTY-813, working capital and general corporate purposes | Jan 8, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$20.00 a share on Jun 17, 2021.
- Price
- US$20.00 a share
- Shares offered
- 10,550,000 shares of common stock
- Offering size
- US$211 million
- Underwriters' option
- Up to 1,582,500 more shares
- Listing
- IPSC on the Nasdaq Global Select Market
- Underwriters
- J.P. Morgan, BofA Securities, SVB Leerink, Piper Sandler · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 26, 2021 |
| Filed publicly | May 28, 2021 |
| Amended twice | Newest Jun 15, 2021 |
| Shares registered with an exchange | Jun 14, 2021 |
| Declared effective by the SEC | Jun 17, 2021 |
| Final prospectus, with the price | Jun 21, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 21, 2021 |
| EFFECT · Notice that a registration is effective | Jun 17, 2021 |
| CERT · Exchange's certificate of listing | Jun 17, 2021 |
| CERT · Exchange's certificate of listing | Jun 16, 2021 |
| CERT · Exchange's certificate of listing | Jun 16, 2021 |
| CORRESP · Letter to the SEC | Jun 15, 2021 |
| CORRESP · Letter to the SEC | Jun 15, 2021 |
| S-1/A · Registration statement, amended | Jun 15, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 14, 2021 |
| S-1/A · Registration statement, amended | Jun 14, 2021 |
All 18 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jun 10, 2021 |
| CORRESP · Letter to the SEC | May 28, 2021 |
| S-1 · Registration statement | May 28, 2021 |
| UPLOAD · Letter from the SEC | May 21, 2021 |
| DRSLTR · Letter to the SEC with a draft | May 5, 2021 |
| DRS/A · Draft registration statement, amended | May 5, 2021 |
| UPLOAD · Letter from the SEC | Apr 23, 2021 |
| DRS · Draft registration statement | Mar 26, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 21, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 109.2M | 6.59M | 2.23M | 5.20M | 1.06M | 0 | 0 | 470.3M | 950.8M |
| Cost of revenue | 13.1M | 13.3M | 13.0M | 10.1M | 4.58M | 1.75M | 249.0K | 467.8M | 888.8M |
| Gross profit | 96.1M | 6.59M | 2.23M | 5.20M | -4.58M | -1.75M | -249.0K | 2.48M | 62.0M |
| Research and development | 95.7M | 107.2M | 92.7M | 97.2M | 75.6M | 39.7M | 14.3M | 9.09M | 11.4M |
| Selling, general and administrative | 24.0M | 33.2M | 34.7M | 31.9M | 19.2M | 9.49M | 5.77M | 81.4M | 108.8M |
| Operating income | -17.3M | -138.1M | -146.5M | -133.8M | -94.9M | -53.9M | -20.0M | ||
| Depreciation and amortization | 13.1M | 13.3M | 13.0M | 8.44M | 3.75M | 1.40M | 249.0K | ||
| EBITDA | -4.17M | -124.8M | -133.5M | -125.4M | -91.1M | -52.5M | -19.8M | ||
| Interest expense | 0 | 540.0K | 1.02M | 1.27M | 381.0K | 0 | 0 | 0 | |
| Income before tax | -9.65M | -124.8M | -134.8M | -130.8M | -95.8M | -53.6M | -244.8M | ||
| Income tax | -68.0K | 1.79M | 1.88M | 91.0K | 43.0K | 1.08M | 1.21M | ||
| Net income | -9.58M | -126.6M | -136.7M | -130.9M | -95.8M | -53.6M | -244.8M | ||
| Earnings per share, basic | -0.14 | -1.61 | -2.30 | -2.27 | -2.96 | -7.16 | -4.46 | ||
| Earnings per share, diluted | -0.14 | -1.61 | -2.30 | -2.96 | -2.96 | -7.16 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 61.9M | 58.4M | 47.3M | 84.3M | 56.4M | 27.2M | 44.1M | 21.5M | 208.0K |
| Short-term investments | 55.3M | 130.9M | 125.4M | 231.2M | 166.4M | 48.5M | 37.5M | ||
| Receivables | 667.0K | 1.52M | 665.0K | 780.0K | 250.0K | 908.0K | 123.0K | ||
| Inventory | -250.0K | 1.88M | 2.34M | 192.9M | 285.8M | ||||
| Current assets | 120.8M | 194.1M | 177.0M | 319.7M | 228.2M | 78.8M | 84.1M | ||
| Property, plant and equipment | 50.0M | 62.1M | 71.7M | 82.8M | 58.0M | 15.4M | 2.49M | 402.1M | 440.9M |
| Total assets | 223.7M | 353.2M | 360.7M | 486.5M | 437.4M | 106.8M | 90.9M | 758.0M | 844.7M |
| Accounts payable | 4.77M | 3.08M | 2.74M | 5.45M | 7.60M | 8.08M | 1.55M | 55.9M | 43.0M |
| Current liabilities | 20.2M | 129.8M | 17.8M | 29.8M | 15.7M | 12.1M | 2.99M | 289.7M | 317.4M |
| Long-term debt | 3.74M | 8.90M | 9.64M | 275.4M | 156.3M | ||||
| Total debt | 43.6M | 53.8M | 48.2M | 10.4M | 10.4M | 9.64M | |||
| Total liabilities | 64.8M | 191.9M | 175.9M | 183.8M | 41.1M | 33.4M | 182.8M | 575.5M | 485.0M |
| Shareholders' equity | 158.9M | 161.4M | 184.8M | 302.7M | 396.2M | -106.4M | -91.9M | 182.5M | 359.7M |
| Shares outstanding | 87.5M | 85.8M | 60.3M | 55.0M | 58.5M | 7.48M | 54.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -103.9M | -110.1M | -88.3M | 14.1M | -89.0M | -41.3M | -16.2M | 104.3M | |
| Capital spending | -848.0K | -154.0K | -13.7M | -30.6M | -45.0M | -9.82M | -2.46M | -11.1M | -29.4M |
| Free cash flow | -104.7M | -110.3M | -102.1M | -16.6M | -134.0M | -51.1M | -18.6M | 74.9M | |
| Cash from investing | 107.5M | 47.5M | 61.1M | -13.1M | -298.3M | -22.8M | -19.8M | ||
| Cash from financing | 173.0K | 74.6M | -9.72M | 27.2M | 417.8M | 47.7M | 74.8M | 98.1M | |
| Share buybacks | 27.2M | 223.9M | |||||||
| Change in cash | 3.80M | 11.9M | -36.9M | 28.1M | 30.4M | -16.3M | 38.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 3, 2026 | Other filings | SEC |
| 8-K · Current report | Oct 2, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 14, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Sep 14, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 9, 2026 | Management or board change | SEC |
| 144 · Notice of proposed sale | Sep 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 16, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2026 | Meeting outcome | SEC |
| 144 · Notice of proposed sale | Jun 12, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 8, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Jun 8, 2026 | Other filings | SEC |
| 424B7 · Prospectus | May 21, 2026 | Offer document | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Apr 27, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 27, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 16, 2026 | Annual report | SEC |
| PRE 14A · Preliminary proxy statement | Apr 16, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 26, 2026 | Current report | SEC |
| 424B5 · Prospectus | Mar 26, 2026 | Offer document | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 12, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 12, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 12, 2026 | Results | SEC |
| 10-K · Annual report | Mar 12, 2026 | Annual report | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Feb 18, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Feb 17, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 5, 2026 | Insider trade | SEC |
| S-3 · Registration statement | Feb 5, 2026 | Offer document | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 23, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jan 12, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 8, 2026 | Material contract | SEC |
| CORRESP · Letter to the SEC | Jan 7, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| S-3/A · Registration statement, amended | Jan 5, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 29, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 12, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 144/A · Notice of proposed sale, amended | Dec 9, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 9, 2025 | Management or board change | SEC |
| 144 · Notice of proposed sale | Dec 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 8, 2025 | Other filings | SEC |
| DEFA14A · Additional proxy material | Dec 2, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Dec 2, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Nov 21, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 8, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 29, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Aug 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| 4 · Change in ownership | Aug 6, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Jul 14, 2025 | Other filings | SEC |
| S-3 · Registration statement | Jul 10, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 7, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 16, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 9, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 9, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 9, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 16, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| 4 · Change in ownership | May 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 5, 2025 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 22, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 22, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 22, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 20, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 19, 2025 | Results | SEC |
| 10-K · Annual report | Mar 19, 2025 | Annual report | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 10, 2025 | Other filings | SEC |
| 8-K · Current report | Feb 28, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 18, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 3, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| 8-K · Current report | Dec 13, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Nov 27, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 5, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 5, 2024 | Quarterly report | SEC |
| 144 · Notice of proposed sale | Nov 4, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 25, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 26, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Sep 16, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 5, 2024 | Other filings | SEC |
This page holds 200 of 447 filings. Open Filings
Cap table
Built by 6ix from Century Therapeutics, Inc.’s releases · as of Nov 5, 2026
- Common shares
- 181,597,002
- Fully diluted
- 181,597,002
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 181,597,002 | Nov 5, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 5, 2026 | 181,597,002 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Eli Casdin Other companies: GeneDx Holdings Corp. (Board Member · Since at least Apr 27, 2022); Standard BioTools Inc. (Director · Since at least Apr 4, 2022); 2Seventy Bio Inc (Director · Mar 20, 2024 – May 13, 2025 · Past); EQRx Inc (Director · Sep 30, 2022 – Sep 30, 2022 · Past); Tenaya Therapeutics, Inc. (Director · Jun 10, 2022 – Nov 17, 2022 · Past); Absci Corporation (Director · Jun 8, 2022 – Jun 8, 2022 · Past) | Director · Jun 9, 2022 – Jun 9, 2022 · Past |
| Cynthia M. Butitta Other companies: Autolus Therapeutics plc (Chair of the Compensation Committee, Member of the Audit Committee · Since at least Mar 18, 2026); Olema Pharmaceuticals, Inc. (Director · Since at least Aug 12, 2020); UroGen Pharma Ltd. (of the Audit Committee · Since at least Jan 1, 2019); Kite Pharma Inc (Chief Operating Officer · Jun 19, 2014 – Oct 3, 2017 · Past) | Director · Since at least Jun 17, 2021 |
| Alessandro Riva Other companies: BeOne Medicines Ltd. Class A (Director · Since at least May 22, 2026); Bicycle Therapeutics PLC (Director · Since at least Jan 2, 2026) | Director · Since at least Jun 12, 2025 |
| Brent Pfeiffenberger Other companies: Corbus Pharmaceuticals Holdings, Inc. (Director · Since at least May 13, 2026); Butterfly Network, Inc. (President and CEO, Director · Mar 7, 2024 – Mar 7, 2024 · Past) | President and CEO, Director · Since at least Dec 4, 2023 |
| Daphne Quimi Other companies: Amylyx Pharmaceuticals, Inc. (Director · Since at least Jan 6, 2022); Amicus Therapeutics Inc (Chief Financial Officer · Oct 1, 2020 – Jan 17, 2023 · Past) | Director · Since at least Oct 1, 2022 |
| Kimberly Blackwell Other companies: Monte Rosa Therapeutics, Inc. (Chief Development Officer, Nucleus RadioPharma · Since at least Apr 12, 2021); Zentalis Pharmaceuticals, Inc. (Chief Executive Officer, Director · Jul 1, 2020 – Feb 1, 2024 · Past) | Director · Since at least Jun 17, 2021 |
| Joseph Truitt Other companies: Larimar Therapeutics, Inc. (BOARD CHAIR · Since at least May 10, 2022) | Director · Since at least Sep 9, 2026 |
| Adrienne Farid | Chief Operations Officer · Since at least Jun 17, 2021 |
| Century Therapeutics Douglas Carr Senior | Vice President · Since at least Oct 14, 2026 |
| Chad Cowan | Chief Scientific Officer · Since at least Nov 13, 2025 |
All 19 people
| Person | Seat |
|---|---|
| Douglas Carr | SVP Finance & Operations · Since at least Jun 17, 2021 |
| Elizabeth Devlin | VP, Head of Development · Since at least Nov 5, 2026 |
| Gregory Russotti | See Remarks · Since at least Jun 9, 2025 |
| Greg Russotti | Chief Technology and Manufacturing Officer · Since at least Nov 4, 2026 |
| Krista Kauppinen | VP, General Counsel & Head of Intellectual Property · Since at least Nov 5, 2026 |
| Martin Patrick Murphy | Director · Since at least Dec 9, 2025 |
| Megan Bilson | Chief People Officer · Since at least Nov 5, 2026 |
| Morgan Conn | Chief Finanical Officer · Oct 14, 2024 – Mar 11, 2025 · Past |
| Rizzuto Carlo | Director · Since at least Jun 12, 2025 |
Log in to ask 6ix AI your own questions about Century Therapeutics, Inc.